Cooperative group research endeavors in small-cell lung cancer

Current and future directions

Randeep Sangha, Primo N. Lara, Alex A. Adjei, Paul Baas, Hak Choy, Laurie E. Gaspar, Glenwood Goss, Nagahiro Saijo, Joan H. Schiller, Everett E. Vokes, David R. Gandara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations designed within the cooperative group system and were a feature of the 2008 ILCC. Small-cell lung cancer (SCLC) represents 15% of all lung cancers diagnosed annually and is characterized by rapid growth kinetics, disseminated metastases, and development of chemotherapy resistance. Many questions remain regarding the optimal use of radiation therapy and approaches for enhancing the effects of chemotherapy to improve clinical outcomes. Herein, we explore and outline the scientific vision of each cooperative group's SCLC research portfolio, as presented at the 2008 ILCC. Highlights include an ongoing Intergroup phase III study exploring differing radiation therapy schemes for limited-stage SCLC and a Southwest Oncology Group 0124 trial establishing platinum/etoposide as the standard of care for untreated extensive-stage SCLC in North America. Continued research efforts sponsored by these groups will represent the future of SCLC diagnosis and management.

Original languageEnglish (US)
Pages (from-to)322-330
Number of pages9
JournalClinical Lung Cancer
Volume10
Issue number5
DOIs
StatePublished - 2009

Fingerprint

Small Cell Lung Carcinoma
Lung Neoplasms
Research
North America
Radiotherapy
Drug Therapy
Etoposide
Standard of Care
Platinum
Direction compound
Japan
Clinical Trials
Neoplasm Metastasis
Growth

Keywords

  • Clinical trials
  • Hyperfractionation
  • Intergroup trials
  • Limited stage
  • Platinum resistance
  • Radiation therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Sangha, R., Lara, P. N., Adjei, A. A., Baas, P., Choy, H., Gaspar, L. E., ... Gandara, D. R. (2009). Cooperative group research endeavors in small-cell lung cancer: Current and future directions. Clinical Lung Cancer, 10(5), 322-330. https://doi.org/10.3816/CLC.2009.n.044

Cooperative group research endeavors in small-cell lung cancer : Current and future directions. / Sangha, Randeep; Lara, Primo N.; Adjei, Alex A.; Baas, Paul; Choy, Hak; Gaspar, Laurie E.; Goss, Glenwood; Saijo, Nagahiro; Schiller, Joan H.; Vokes, Everett E.; Gandara, David R.

In: Clinical Lung Cancer, Vol. 10, No. 5, 2009, p. 322-330.

Research output: Contribution to journalArticle

Sangha, R, Lara, PN, Adjei, AA, Baas, P, Choy, H, Gaspar, LE, Goss, G, Saijo, N, Schiller, JH, Vokes, EE & Gandara, DR 2009, 'Cooperative group research endeavors in small-cell lung cancer: Current and future directions', Clinical Lung Cancer, vol. 10, no. 5, pp. 322-330. https://doi.org/10.3816/CLC.2009.n.044
Sangha, Randeep ; Lara, Primo N. ; Adjei, Alex A. ; Baas, Paul ; Choy, Hak ; Gaspar, Laurie E. ; Goss, Glenwood ; Saijo, Nagahiro ; Schiller, Joan H. ; Vokes, Everett E. ; Gandara, David R. / Cooperative group research endeavors in small-cell lung cancer : Current and future directions. In: Clinical Lung Cancer. 2009 ; Vol. 10, No. 5. pp. 322-330.
@article{9fbd8a340a37430f966744e6f9f2d25e,
title = "Cooperative group research endeavors in small-cell lung cancer: Current and future directions",
abstract = "The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations designed within the cooperative group system and were a feature of the 2008 ILCC. Small-cell lung cancer (SCLC) represents 15{\%} of all lung cancers diagnosed annually and is characterized by rapid growth kinetics, disseminated metastases, and development of chemotherapy resistance. Many questions remain regarding the optimal use of radiation therapy and approaches for enhancing the effects of chemotherapy to improve clinical outcomes. Herein, we explore and outline the scientific vision of each cooperative group's SCLC research portfolio, as presented at the 2008 ILCC. Highlights include an ongoing Intergroup phase III study exploring differing radiation therapy schemes for limited-stage SCLC and a Southwest Oncology Group 0124 trial establishing platinum/etoposide as the standard of care for untreated extensive-stage SCLC in North America. Continued research efforts sponsored by these groups will represent the future of SCLC diagnosis and management.",
keywords = "Clinical trials, Hyperfractionation, Intergroup trials, Limited stage, Platinum resistance, Radiation therapy",
author = "Randeep Sangha and Lara, {Primo N.} and Adjei, {Alex A.} and Paul Baas and Hak Choy and Gaspar, {Laurie E.} and Glenwood Goss and Nagahiro Saijo and Schiller, {Joan H.} and Vokes, {Everett E.} and Gandara, {David R.}",
year = "2009",
doi = "10.3816/CLC.2009.n.044",
language = "English (US)",
volume = "10",
pages = "322--330",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Cooperative group research endeavors in small-cell lung cancer

T2 - Current and future directions

AU - Sangha, Randeep

AU - Lara, Primo N.

AU - Adjei, Alex A.

AU - Baas, Paul

AU - Choy, Hak

AU - Gaspar, Laurie E.

AU - Goss, Glenwood

AU - Saijo, Nagahiro

AU - Schiller, Joan H.

AU - Vokes, Everett E.

AU - Gandara, David R.

PY - 2009

Y1 - 2009

N2 - The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations designed within the cooperative group system and were a feature of the 2008 ILCC. Small-cell lung cancer (SCLC) represents 15% of all lung cancers diagnosed annually and is characterized by rapid growth kinetics, disseminated metastases, and development of chemotherapy resistance. Many questions remain regarding the optimal use of radiation therapy and approaches for enhancing the effects of chemotherapy to improve clinical outcomes. Herein, we explore and outline the scientific vision of each cooperative group's SCLC research portfolio, as presented at the 2008 ILCC. Highlights include an ongoing Intergroup phase III study exploring differing radiation therapy schemes for limited-stage SCLC and a Southwest Oncology Group 0124 trial establishing platinum/etoposide as the standard of care for untreated extensive-stage SCLC in North America. Continued research efforts sponsored by these groups will represent the future of SCLC diagnosis and management.

AB - The International Lung Cancer Congress (ILCC), now in its ninth year, is a key forum for representatives of cooperative groups in North America, Europe, and Japan to discuss ongoing and planned clinical trials in lung cancer. Many of the significant strides in lung cancer treatment often originate from investigations designed within the cooperative group system and were a feature of the 2008 ILCC. Small-cell lung cancer (SCLC) represents 15% of all lung cancers diagnosed annually and is characterized by rapid growth kinetics, disseminated metastases, and development of chemotherapy resistance. Many questions remain regarding the optimal use of radiation therapy and approaches for enhancing the effects of chemotherapy to improve clinical outcomes. Herein, we explore and outline the scientific vision of each cooperative group's SCLC research portfolio, as presented at the 2008 ILCC. Highlights include an ongoing Intergroup phase III study exploring differing radiation therapy schemes for limited-stage SCLC and a Southwest Oncology Group 0124 trial establishing platinum/etoposide as the standard of care for untreated extensive-stage SCLC in North America. Continued research efforts sponsored by these groups will represent the future of SCLC diagnosis and management.

KW - Clinical trials

KW - Hyperfractionation

KW - Intergroup trials

KW - Limited stage

KW - Platinum resistance

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=77249165606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249165606&partnerID=8YFLogxK

U2 - 10.3816/CLC.2009.n.044

DO - 10.3816/CLC.2009.n.044

M3 - Article

VL - 10

SP - 322

EP - 330

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 5

ER -